Tolerability and adherence to adjuvant abemaciclib in hormone receptor-positive, HER2-negative, node-positive high-risk early breast cancer: a real-world study
Carl Rosander, Karolina Larsson, Per Karlsson · 2026
Read Tolerability and adherence to adjuvant abemaciclib in hormone receptor-positive, HER2-negative, node-positive high-risk early breast cancer: a real-world study by Carl Rosander, Karolina Larsson, Per Karlsson (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13563436.txt.
Description
Rosander, Larsson, and Karlsson follow how real patients cope with a breast cancer drug given after surgery to stop the cancer returning. The drug, abemaciclib, pairs with hormone therapy but often causes side effects that make people quit. Their hospital tried easing patients onto the full dose gradually.
The study covered 69 patients, older and frailer than trial volunteers. About half stayed on the full dose at 12 weeks, fewer than in the big trials, yet 94 percent stayed on some dose. Quits were driven mostly by mild but grinding side effects. Care visits piled up past a thousand. The authors weigh gentler starts against steady persistence.
Catalog record
| CREATOR | Carl Rosander, Karolina Larsson, Per Karlsson |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |